Linda Werner, MD
Endocrinology, Diabetes & Metabolism · Trumbull, CTNPI 1104811546
Payments from drug & device makers
Across 180 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$427
- Sanofi-aventis U.S. LLC$401
- Lilly USA, LLC$349
- Corcept Therapeutics$303
- AstraZeneca$277
- Novo Nordisk$215
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,85492%
- Education$2508%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 36 | $427 |
| Sanofi-aventis U.S. LLC | 17 | $401 |
| Lilly USA, LLC | 28 | $349 |
| Corcept Therapeutics | 9 | $303 |
| AstraZeneca(2 entities) | 14 | $277 |
| Novo Nordisk | 15 | $215 |
| Amneal Pharmaceuticals LLC | 10 | $186 |
| IBSA Pharma Inc. | 4 | $78 |
| AbbVie | 4 | $75 |
| Boehringer Ingelheim | 5 | $71 |
| Amarin Pharma, Inc. | 3 | $64 |
| Aytu Biopharma, Inc. | 3 | $60 |
| Merck | 4 | $53 |
| Johnson & Johnson | 3 | $48 |
| Dexcom, Inc. | 1 | $45 |
| Eisai Inc. | 2 | $45 |
| Insulet Corporation | 3 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $40 |
| Vivus LLC | 2 | $36 |
| Radius Health, Inc. | 2 | $35 |
| Currax Pharmaceuticals LLC | 2 | $33 |
| Bayer | 1 | $31 |
| Esperion Therapeutics, Inc. | 1 | $28 |
| Nalpropion Pharmaceuticals LLC | 2 | $27 |
| Abbott | 1 | $24 |
| Medtronic | 1 | $23 |
| Pfizer | 2 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Endo Pharmaceuticals Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$125
How this compares
$3,104 in reported general payments places this provider in the 60th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 178 | $250,715 |
| MounjaroTirzepatide | 88 | $119,110 |
| TrulicityDulaglutide | 66 | $90,199 |
| JardianceEmpagliflozin | 57 | $70,686 |
| JanuviaSitagliptin Phosphate | 47 | $61,463 |
| ProliaDenosumab | 33 | $57,407 |
| SynthroidLevothyroxine Sodium | 452 | $51,828 |
| FarxigaDapagliflozin Propanediol | 32 | $34,187 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 32 | $34,170 |
| InvokanaCanagliflozin | 17 | $25,018 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $21,879 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $19,510 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $12,186 |
| Levothyroxine Sodium | 1,134 | $11,624 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $11,521 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $215 | $250,715178 claims |
| Lilly USA, LLCMounjaro, Trulicity | $349 | $209,309154 claims |
| MerckJanuvia, Janumet Xr, Janumet | $53 | $115,14491 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $71 | $82,20768 claims |
| AmgenProlia | $427 | $57,40733 claims |
| AbbVieSynthroid, Armour Thyroid | $75 | $53,844476 claims |
| AstraZenecaFarxiga | $277 | $34,18732 claims |
| Johnson & JohnsonInvokana | $48 | $25,01817 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $186 | $14,6261,178 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in Trumbull
- Glenn RichTrumbull$210K
- Judith CastilloTrumbull$37K
- Jonathan FillmoreTrumbull$12K
- Joseph RosaTrumbull$8K
- Agnieszka GrochowalskaTrumbull$8K
- Erika StrohmayerTrumbull$4K
- Ania JastreboffNew Haven$2.2M
- Ilja HulinskyBridgeport$1.6M
- Gerald ShulmanNew Haven$1M
- Karl InsognaNew Haven$903K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.